Allergy Immunotherapy Market Introduction and Overview
According to SPER Market Research, the Global Allergy Immunotherapy Market is estimated to reach USD 4.54 billion by 2034 with a CAGR of 8.99%.
The report includes an in-depth analysis of the Global Allergy Immunotherapy Market, including market size and trends, product mix, Applications, and supplier analysis. The Allergy Immunotherapy market growth expansion include the launch of novel sublingual immunotherapies in emerging nations and the rising prevalence of different allergies. It is anticipated that the growing number of allergy cases would increase demand for allergy immunotherapy, which will fuel market growth in the upcoming years. Additionally, the market's growth is being greatly impacted by firms' growing emphasis on research and development to provide novel allergy immunotherapies to address important unmet medical needs. However, the high cost of treatment and low medication adherence are expected to impede market growth. Although allergy immunotherapy has various advantages, poor patient adherence is driven by variables such as low awareness and insufficient reimbursement options.
By Treatment Type: The market was dominated by the Subcutaneous Immunotherapy (SCIT) sector, mainly because of its established efficacy and lengthy track record of effectively treating allergy conditions. It is well acclaimed for making patients less sensitive to particular allergens, which significantly reduces symptoms. Patients with numerous sensitivities can benefit greatly from SCIT's comprehensive allergen coverage, which addresses triggers like pollen, dust mites, and pet dander. It has thus been shown to be efficacious, and its broad range of applications contribute significantly to its domination in the treatment of allergies.
By Type: The tablets segment leads the market due to the growing popularity of Sublingual Immunotherapy (SLIT) products, which offer a convenient, non-invasive alternative to traditional allergy shots. SLIT tablets enable at-home self-administration, reducing the need for frequent healthcare visits and improving patient comfort. Increased awareness of SLIT’s benefits, such as fewer systemic reactions, has led to higher prescriptions. Meanwhile, the drops segment is expected to grow steadily, as they offer easy self-administration, enhanced comfort, and dosing flexibility, making them especially appealing for patients with diverse allergy triggers.
By Allergy Type: The allergic rhinitis segment leads the market due to rising urbanization, pollution, and climate change, which have increased exposure to allergens and prevalence of the condition. Growing awareness and longer pollen seasons further contribute to the demand for treatments. Meanwhile, the other segment is expanding as more allergic conditions, like food and insect allergies, gain recognition, driving the need for targeted immunotherapy solutions.
By Distribution Channel: Hospital pharmacies dominate the industry because of their solid supplier relationships and capacity to work with immunologists and allergists to provide individualized treatment plans. They guarantee steady product availability by offering a broad variety of modern immunotherapy choices. Online pharmacies, on the other hand, are expanding rapidly due to the growth of e-commerce, home delivery, competitive pricing, the growing popularity of self-medication, and remote consultations.
By Regional Insights: The allergy immunotherapy market in North America holds a significant share, driven by the high number of individuals affected by allergic conditions such as allergic rhinitis, asthma, and food allergies. With millions impacted, the demand for effective treatment options, particularly immunotherapy, continues to rise as patients seek long-term relief. Increased awareness of available treatments further boosts this demand, supporting the market's growth in the region.
Market Competitive Landscape:
The market is highly consolidated. Some of the market key players are ALK-Abello A/S, Allergy Therapeutics, ASIT Biotech, Circassia, DESENTUM OY, DMK Pharmaceuticals, DVB Technologies SA, HAL Allergy B.V., HollisterStier Allergy, LETIPharma, and others.
Recent Developments:
- Viatris and Lexicon Pharmaceuticals signed a deal in October 2024, giving Viatris the rights to sell sotagliflozin in all markets outside of the US and Europe. Approved in May 2023, sotagliflozin is intended to lower cardiovascular risks in patients with type 2 diabetes and heart failure. Viatris will manage all regulatory and commercialization activities, and the agreement includes an upfront payment of USD 25 million as well as possible milestone payments.
- Merck and Siemens fortified their collaboration in September 2024 by signing a Memorandum of Understanding to boost smart manufacturing, which integrates cutting-edge technologies for better manufacturing procedures. This partnership seeks to use modular production to expedite product development while giving sustainability and adaptability first priority. Merck is anticipated to use cutting-edge hardware and software solutions to minimize time-to-market and streamline operations by utilizing the Siemens Xcelerator platform.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Treatment Type, By Type, By Allergy Type, By Distribution Channel. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | ALK-Abelló A/S, Allergy Therapeutics, ASIT Biotech, Circassia, DESENTUM OY, DMK Pharmaceuticals, DVB Technologies SA, HAL Allergy B.V., HollisterStier Allergy, LETIPharma, and others. |
Key Topics Covered in the Report:
- Global Allergy Immunotherapy Market Size (FY’2021-FY’2034)
- Overview of Global Allergy Immunotherapy Market
- Segmentation of Global Allergy Immunotherapy Market By Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy)
- Segmentation of Global Allergy Immunotherapy Market By Type (Tablets, Drops)
- Segmentation of Global Allergy Immunotherapy Market By Allergy Type, (Allergic Rhinitis, Allergic Asthma, Others)
- Segmentation of Global Allergy Immunotherapy Market By Distribution Channel, (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- Statistical Snap of Global Allergy Immunotherapy Market
- Expansion Analysis of Global Allergy Immunotherapy Market
- Problems and Obstacles in Global Allergy Immunotherapy Market
- Competitive Landscape in the Global Allergy Immunotherapy Market
- Details on Current Investment in Global Allergy Immunotherapy Market
- Competitive Analysis of Global Allergy Immunotherapy Market
- Prominent Players in the Global Allergy Immunotherapy Market
- SWOT Analysis of Global Allergy Immunotherapy Market
- Global Allergy Immunotherapy Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Allergy Immunotherapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Allergy Immunotherapy Market
7. Global Allergy Immunotherapy Market, By Treatment Type, (USD Million) 2021-2034
7.1. Subcutaneous Immunotherapy
7.2. Sublingual Immunotherapy
8. Global Allergy Immunotherapy Market, By Type, (USD Million) 2021-2034
8.1. Tablets
8.2. Drops
9. Global Allergy Immunotherapy Market, By Allergy Type, (USD Million) 2021-2034
9.1. Allergic Rhinitis
9.2. Allergic Asthma
9.3. Others
10. Global Allergy Immunotherapy Market, By Distribution Channel, (USD Million) 2021-2034
10.1. Hospital Pharmacy
10.2. Retail Pharmacy
10.3. Online Pharmacy
11. Global Allergy Immunotherapy Market, (USD Million) 2021-2034
11.1. Global Allergy Immunotherapy Market Size and Market Share
12. Global Allergy Immunotherapy Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. ALK-Abello A/S
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Allergy Therapeutics
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. ASIT Biotech
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Circassia
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. DESENTUM OY
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. DMK Pharmaceuticals
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. DVB Technologies SA
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. HAL Allergy B.V.
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. HollisterStier Allergy
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. LETIPharma
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links